Report error Found 18 Enz. Inhib. hit(s) with all data for entry = 9830
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataIC50: 7.94nMAssay Description:1. A 10 mM test compound was dissolved in 100% DMSO and serially diluted 1 in 4. 100 nL of this dilution series was then added to a 384 well, v botto...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataIC50: 7.94nMAssay Description:1. A 10 mM test compound was dissolved in 100% DMSO and serially diluted 1 in 4. 100 nL of this dilution series was then added to a 384 well, v botto...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataIC50: 7.94nMAssay Description: LRRKtide Detection settings: Q1 mass 644.8 Da, Q3 mass 638.8, declustering potential 76 volts, collision energy 37 volts, CXP 34 volts Phosp...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataIC50: 7.94nMAssay Description:1. A 10 mM test compound was dissolved in 100% DMSO and serially diluted 1 in 4. 100 nL of this dilution series was then added to a 384 well, v botto...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataIC50: 10nMAssay Description:1. A 10 mM test compound was dissolved in 100% DMSO and serially diluted 1 in 4. 100 nL of this dilution series was then added to a 384 well, v botto...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataIC50: 10nMAssay Description:1. A 10 mM test compound was dissolved in 100% DMSO and serially diluted 1 in 4. 100 nL of this dilution series was then added to a 384 well, v botto...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataIC50: 12.6nMAssay Description:1. A 10 mM test compound was dissolved in 100% DMSO and serially diluted 1 in 4. 100 nL of this dilution series was then added to a 384 well, v botto...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataIC50: 12.6nMAssay Description:1. A 10 mM test compound was dissolved in 100% DMSO and serially diluted 1 in 4. 100 nL of this dilution series was then added to a 384 well, v botto...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataIC50: 12.6nMAssay Description: LRRKtide Detection settings: Q1 mass 644.8 Da, Q3 mass 638.8, declustering potential 76 volts, collision energy 37 volts, CXP 34 volts Phosp...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataIC50: 12.6nMAssay Description:1. A 10 mM test compound was dissolved in 100% DMSO and serially diluted 1 in 4. 100 nL of this dilution series was then added to a 384 well, v botto...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataIC50: 12.6nMAssay Description: LRRKtide Detection settings: Q1 mass 644.8 Da, Q3 mass 638.8, declustering potential 76 volts, collision energy 37 volts, CXP 34 volts Phosp...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataIC50: 12.6nMAssay Description:1. A 10 mM test compound was dissolved in 100% DMSO and serially diluted 1 in 4. 100 nL of this dilution series was then added to a 384 well, v botto...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataIC50: 20nMAssay Description: LRRKtide Detection settings: Q1 mass 644.8 Da, Q3 mass 638.8, declustering potential 76 volts, collision energy 37 volts, CXP 34 volts Phosp...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataIC50: 20nMAssay Description: LRRKtide Detection settings: Q1 mass 644.8 Da, Q3 mass 638.8, declustering potential 76 volts, collision energy 37 volts, CXP 34 volts Phosp...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataIC50: 25.1nMAssay Description: LRRKtide Detection settings: Q1 mass 644.8 Da, Q3 mass 638.8, declustering potential 76 volts, collision energy 37 volts, CXP 34 volts Phosp...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataIC50: 25.1nMAssay Description:1. A 10 mM test compound was dissolved in 100% DMSO and serially diluted 1 in 4. 100 nL of this dilution series was then added to a 384 well, v botto...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataIC50: 31.6nMAssay Description:1. A 10 mM test compound was dissolved in 100% DMSO and serially diluted 1 in 4. 100 nL of this dilution series was then added to a 384 well, v botto...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataIC50: 251nMAssay Description: LRRKtide Detection settings: Q1 mass 644.8 Da, Q3 mass 638.8, declustering potential 76 volts, collision energy 37 volts, CXP 34 volts Phosp...More data for this Ligand-Target Pair















